ProfileGDS5678 / 1453484_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 50% 50% 49% 49% 50% 49% 49% 50% 50% 50% 49% 51% 50% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2920251
GSM967853U87-EV human glioblastoma xenograft - Control 23.1921550
GSM967854U87-EV human glioblastoma xenograft - Control 33.1909350
GSM967855U87-EV human glioblastoma xenograft - Control 43.1058949
GSM967856U87-EV human glioblastoma xenograft - Control 53.1220549
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2842850
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2336649
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1706149
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1668350
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.186250
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1775950
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1289149
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2262551
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1815750